Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Combo Therapy Outcomes for West Syndrome No Better Than Monotherapy

Key clinical point: Combining hormonal therapy with vigabatrin in infants with West syndrome didn’t result in better developmental or epilepsy outcomes at 18 months than with hormonal therapy alone.

Major finding: The mean Vineland Adaptive Behavior Scales composite score at 18 months was 73.9 in the combination therapy group and 72.7 in children randomized to hormonal therapy alone.

Study details: This was an international, open-label study in which 377 patients with infantile spasms and hypsarrhythmia were randomized to hormonal therapy alone or in combination with vigabatrin.

Disclosures: The study was sponsored by the U.K. National Institute of Health Research and other noncommercial entities.

Citation:

EXPERT ANALYSIS FROM IEC 2019